Kitahara Hideki, Kobayashi Yoshio, Fujimoto Yoshihide, Nakamura Yoshitake, Nakayama Takashi, Kuroda Nakabumi, Himi Toshiharu, Miyazaki Akira, Komuro Issei
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Circ J. 2008 Jan;72(1):168-9. doi: 10.1253/circj.72.168.
There is little information about the efficacy of ticlopidine plus aspirin after sirolimus-eluting stent (SES) implantation.
The incidence of stent thrombosis was evaluated in 1,029 patients receiving ticlopidine and aspirin after SES deployment. Clinical follow-up was obtained in 98.9% (mean follow-up 17.0+/-7.9 months). Early stent thrombosis was observed in 5 patients (0.49%). There was 1 case each of late (0.1%) and very late stent thrombosis (0.1%).
Late and very late stent thrombosis in Japanese patients receiving ticlopidine and aspirin after SES deployment occurs infrequently.
关于西罗莫司洗脱支架（SES）植入后噻氯匹定联合阿司匹林的疗效信息较少。
对1029例SES植入后接受噻氯匹定和阿司匹林治疗的患者评估支架血栓形成的发生率。98.9%的患者获得了临床随访（平均随访17.0±7.9个月）。5例患者（0.49%）发生早期支架血栓形成。晚期（0.1%）和极晚期支架血栓形成各有1例（0.1%）。
日本患者在SES植入后接受噻氯匹定和阿司匹林治疗时，晚期和极晚期支架血栓形成发生率较低。
